Loading…
Based on limited metadata with no full letter text available, this FDA Warning Letter issued to Rablon in March 2019 concerns drug manufacturing or distribution practices. While the specific violation details are not provided in the available metadata, the warning indicates regulatory concerns within FDA's drug oversight authority. Without access to the complete letter, the precise nature of the compliance issues and their scope cannot be determined from this summary information alone.